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Local radiotherapy (RT) plus intratumoral dendritic cell (DC) injection can mediate
immunological response. We hypothesized that co-injection of exogenous
recombinant heat shock protein 70 (rHsp70) in combination with RT-DC could be
as effective as co-injection of HSP-peptide for evoking specific immune response.
rHsp70-prostate-specific antigen (rHSP70C′-PSA) and α-fetoprotein (rHSP70C′-AFP) were
used to compare specific response. Growth inhibition of the tumor and the systemic
anti-tumor immune response were measured on CT26/PSA and CT26/AFP mice model.
Intratumoral co-injection of rHsp70 and DC into the irradiated tumor site induced a more
potent anti-tumor immune response than injection of DC alone. rHsp70 was as effective
as rHsp70C′-PSA or rHsp70C′-AFP in inducing a tumor-specific cytotoxic T lymphocyte
response or tumor growth delay. These results demonstrate that co-administration with
rHsp70 and RT could be a simple and effective source of tumor antigens to achieve RT-DC
immunotherapy protocol and easy to apply in clinical use.
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INTRODUCTION
The tumor microenvironment (TME) is an important factor in
cancer treatment (Formenti and Demaria, 2009). The effects of
radiotherapy (RT) and immunotherapy are theoretically syner-
gistic and complimentary to each other (Ferrara et al., 2009;
Formenti and Demaria, 2009). Creating a favorable host anti-
tumor immune microenvironment by in situ delivery of cytokine
genes into the peritumoral site before RT results in better radio-
responsiveness and systemic anticancer immunity (Wang et al.,
2008). On the other hand, immunotherapy given after RT takes
advantages of the release of tumor antigens from apoptotic irra-
diated tumor cells, which might turn local apoptosis into a
systemic immune response (Friedman, 2002; Lugade et al., 2008;
Teitz-Tennenbaum et al., 2008).
Heat shock proteins (HSPs) are overexpressed in various con-
ditions of stress as stress response proteins (Zhu et al., 1996) and
assist with the folding of newly translated proteins and facilitate
proteolytic degradation of unstable proteins. HSPs purified from
a given cancer elicit protective immunity specific to that particular
cancer (Bukau and Horwich, 1998; Chen et al., 2009). Tumor-
specific peptides are non-covalently bound to HSPs (Udono and
Srivastava, 1994; Tamura et al., 1997). HSP-peptide complexes
provoke specific protective immunity in inbred mice bearing
the same specific type of tumor (Chen et al., 2004). Cancer
treatments, such as chemotherapy, RT, and hyperthermia, have
been shown to induce expression of intracellular HSPs (Hettinga
et al., 1996; Calini et al., 2003; Yang et al., 2003; Grivicich et al.,
2007), which protects tumor cells from further stress, apoptosis,
and DNA damage (Hettinga et al., 1996; Calini et al., 2003).
Endogenous HSP-peptide complexes must be released into the
TME in order to stimulate the immune system (Baronzio et al.,
2006).
Dendritic cells (DCs) that have infiltrated in the TME are
responsible for antigen uptake and maturation in the drain-
ing lymph nodes, and provide the basis for generating effective
anti-tumor immune responses (Banchereau and Steinman, 1998).
Teitz-Tennenbaum et al. (2008) reported that radiation enhances
antigen acquirement by DCs, but this radiation-enhanced load-
ing of DCs does not change the TME, although it improves
cross-priming of T cells in the draining lymph nodes. HSPs can
be released passively or actively (Johnson and Fleshner, 2006).
Leaderless proteins, such asHsp70, are secreted by a non-classical,
vesicle-mediated secretory pathway, a process requiring ATP
(Johnson and Fleshner, 2006). Hsp70 released from tumors exists
as the free form or binds to adjacent cells through an autocrine
or paracrine mechanism (Mambula and Calderwood, 2006). The
preparation of specific HSP-peptide complexes is tedious and,
theoretically, any specific immunotherapy may be failed when
antigen shifts.
Most of cancer vaccines composed tumor-specific antigens
and adjuvant to active immune system (Anderson and Schneider,
2007). However, single tumor-specific antigen could not apply
for every clinical patient. TME may provide several important
antigens, functional immunological cells and cytokines milieu for
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immunotherapy if manipulated appropriately (Kaufman, 2004;
Petrulio et al., 2006). Thus, using irradiated TME as source of
antigens may elicit more effective immunoresponse feasible for
clinical application. We hypothesized that an extracellular sup-
ply of recombinant Hsp70 (rHsp70) might be as effective as
individually prepared HSP-peptide complexes in eliciting specific
immunity when DC immunotherapy is combined with RT.
In this study, we demonstrated that intratumoral co-injection
of rHsp70 with DCs after RT is an attractive and effective
immunotherapy protocol. We also found that exogenous rHsp70
was as effective as HSP-peptide complex.
MATERIALS ANDMETHODS
CELL LINES AND MICE
CT-26, a murine colon carcinoma cell line derived from a
BALB/c mouse, was purchased from the Culture Collection and
ResearchCenter (Hsinchu,Taiwan)and fresh batches were thawed
every year. CT-26/prostate-specific antigen (PSA) and CT-26/α-
fetoprotein (AFP) were the CT-26 cell line transfected with
human PSA and AFP cDNA. The PSA cDNA gene (from human
prostate cancer cell line, PC-3) and AFP cDNA gene (from human
hepatoma cell line, Hep 3B) were cloned into the eukaryotic
expression vector PCR3.1 under the control of the CMV pro-
moter (Invitrogen, San Diego, CA, USA). Transfected cells were
selected in medium containing G418 and protein expression
confirmed by Western blotting. All cell lines were maintained
in Dulbecco’s modified Eagle medium (DMEM) supplemented
with 10% fetal bovine serum (FBS), 100 ng/ml of streptomycin,
and 100U/ml of penicillin (Invitrogen). No further authenti-
cation was used, but the expression of PSA and AFP antigens
was tested during the experiments. Female BALB/c mice were
obtained from the National Science Council Animal Center,
Taipei, Taiwan and were used between 6 and 8 weeks of age. The
studies were approved by the Institutional Animal Care and Use
Committee of the Shin KongWu Ho-SuMemorial Hospital prior
to initiation.
EXPRESSION AND PURIFICATION OF Hsp70, Hsp70C’-PSA, AFP, AND
Hsp70C’-AFP
To generate the Hsp70 expression plasmid pRSETA/Hsp70, the
Hsp70 gene was cloned into the BamHI site of the pRSETA vec-
tor with His-tag (Invitrogen). The Hsp70C′ sequence, consisting
of the terminal 735 nucleotides that code for the 28 kDa car-
boxyl terminal fragment of Hsp70 (amino acids 397–641), was
also cloned into this site, generating the plasmid pRSET/Hsp70C′,
which served as the backbone for the construction of the tumor
antigen-Hsp70C′ expression plasmid. The DNA fragment of PSA
and AFP isolated from pCRII/PSA and pCRII/AFP was ligated
into pRSET/HspC’ vector to produce the Hsp70C′-PSA and
Hsp70C′-AFP fusion protein. All plasmids were transfected into
BL21 (DE3) PLysS or BL21 (DE3) RIL (Promega, Wisconsin,
USA) E. coli hosts, which were cultured with shaking at 37◦C,
and protein expression was induced using 0.1mM isopropyl-
β-thiogalactoside. The recombinant Hsp70, Hsp70C′-PSA and
Hsp70C′-AFP expressed as fusion proteins carrying a His tag were
analyzed by SDS polyacrylamide gel electrophoresis and Western
blotting using an anti-His monoclonal antibody (Invitrogen),
and were purified on a nickel column under denaturing con-
ditions following the manufacturer’s instructions (Qiagen Inc.,
CA, USA). A polymyxin B agarose column (Pierce, Rockfold, IL)
was used to remove endotoxin. Endotoxin levels in the purified
Hsp70, Hsp70C′-PSA, and Hsp70C′-AFP were tested using the
Limulus amebocyte lysate assay (Associates of Cape Cod, Inc.,
Cape Cod, MA) and were below the detection limit of the kit
(<0.1 EU/ml).
GENERATION OF BONE MARROW-DERIVED DENDRITIC CELLS
Bone marrow-derived DCs (BM-DCs) were generated as
described previously (Wang et al., 2008). Briefly, BM-DCs were
isolated from BALB/c mice by culturing red blood cell-depleted
BM cells in complete medium (RPMI 1640 supplemented with
10% FBS, L-glutamine, and 5mM 2-mercaptoethanol) contain-
ing 20 ng/ml of recombinant mouse GM-CSF (Peprotech, Rocky
Hill, NJ, USA) at 37◦C in a humidified atmosphere with 5%
CO2 and were fed every 3rd day with medium containing fresh
GM-CSF. On day 9 of culture, non-adherent cells were har-
vested, washed once in complete medium, and examined for DC
surface marker expression [MHC class II molecule I-Ad/I-Ed,
CD80 (B7-1), CD86 (B7-2), CD11c, and DEC205]. The BM-DCs
(5 − 10 × 105) were stained with 50μl of FITC-conjugated anti-
bodies in phosphate-buffered saline (PBS) containing 1% bovine
serum albumin (BSA) and 0.1% azide, which also served as the
washing buffer, then were subjected to fluorescence-activated cell
sorting (FACS) analysis using a FASCalibur flow cytometer (BD
Bioscience, San Diego, CA, USA). Cells were also stained with the
corresponding isotype-matched control IgG (BD Pharmingen,
San Diego, CA, USA).
CYTOKINE RELEASE ASSAY
CT26/PSA cells were treated with 75Gy of RT and left for 24 h
at 37◦C for apoptosis to occur, then were co-cultured for 24 h
at 37◦C with day 9 BM-DCs and 10μg/ml of BSA, Hsp70 or
Hsp70C′-PSA; 10μg/ml of polymyxin B (Sigma) was added to
one set of cultures to eliminate any effect of LPS. The cul-
ture supernatants were harvested and tumor necrosis factor
α(TNF-α) and interleukin (IL)-12 measured using an enzyme-
linked immunosorbent assay (ELISA) (Endogen, Rockfold, IL).
IMMUNOFLUORESCENCE MICROSCOPY
The cells were co-cultured as described in the previous sec-
tion, then were plated onto glass slides and immediately fixed
with 3.7% paraformaldehyde for 15min; this and all subse-
quent steps were at room temperature. The cells were washed
once with PBS and blocked with blocking buffer (PBS +
3% BSA) for 30min, then were permeabilized by incuba-
tion with 0.1% Triton X-100 (Sigma) in PBS for 15min.
The cells were next washed once with PBS, incubated for 1 h
with AlexaFluor 647-conjugated anti-MHC class II monoclonal
antibody (BioLegend, San Diego, CA, USA) and Alexa Fluor
488-conjugated anti-lysosomal-associated membrane protein 1
(LAMP1) monoclonal antibody (CD107a; BioLegend), followed
by five washes in PBS containing 0.05% Tween 20. The slides were
then mounted in aqueous mounting solution using a coverglass
(Fisher Scientific) before confocal fluorescent microscopy. Images
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were acquired using an Olympus FV1000 microscope (Melville,
NY, USA).
IMMUNOHISTOCHEMISTRY
For immunohistochemical studies, the tumor was resected and
fixed in 10% formalin for 24 h. The formalin-fixed tissues were
embedded in paraffin and 5μm paraffin sections were prepared
on slides precoated with 0.1% poly-L-lysine. The paraffin sec-
tions were then deparaffinzed with xylene and rehydrated in a
graded series of ethanol. T cells were identified using a mono-
clonal anti-CD3 antibody (clone 145−2C11, BD Pharmingen).
The sections were pre-incubated with a 1:20 dilution of nor-
mal rabbit serum, then sequentially incubated for 30–60min at
37◦C with optimal dilutions of anti-CD3 antibody, biotinylated
rabbit anti-mouse IgG, and horseradish peroxidase-conjugated
streptavidin (Zymed, South San Francisco, CA), with PBS washes
between incubations. Peroxidase activity was detected using
0.02 % diaminobenzidine tetrahydrochloride containing 0.005%
hydrogen peroxide. The sections were then counterstained with
hematoxylin. The immunoreaction for CD3 in lymphocytes was
evaluated independently by two pathologists and graded as fol-
lows: (−) = no positive cells, (+) = 1 − 25% of the cells stained,
(++)= 26 − 50% of the cells stained and (+ + +)= 51 − 100%
of the cells stained.
ANIMAL STUDY
BALB/c mice were injected subcutaneously in the left flank with
1 × 105 CT-26/PSA or CT-26/AFP tumor cells on day 0. At day
14 after injection, the mice received local irradiation with 8Gy,
then, on the following day, 5 × 105 syngeneic DCs or PBS in 25μl
were injected into the tumor area. In some groups, the DCs were
mixed with 50μg of rHsp70, rHsp70C′-PSA, rAFP or rHsp70C′-
AFP fusion protein before injection. The size of the tumor was
measured at least three times each week and recorded as length
(L) and width (W) and the tumor volumes calculated as L ×
W2/2. The tumor volume ratio was determined as the tumor
volume after treatment divided by the initial tumor volume
(day 14).
CYTOTOXICITY T LYMPHOCYTE (CTL) ASSAY
On day 35 after tumor injection, the mice were killed and
their spleens harvested. Erythrocyte-depleted splenocytes (1 ×
106 cells/ml) were cultured in vitro with mitomycin C-treated
CT26/PSA tumor cells (1 × 106 cells/ml) in 24-well plates for
5 days, with 50U/ml of recombinant human IL-2 (Proleukin;
Novartis Pharmaceuticals, East Hanover, NJ) being added each
day. On day 5, the cells were collected, dead cells removed on
a density gradient, and the viable cells tested for specific cyto-
toxicity in a standard 5-hr chromium-51 (51Cr)-release assay.
The percentage specific cytotoxicity was calculated as 100 ×
[(experimental release – spontaneous release)/(maximal release –
spontaneous release)].
STATISTICAL ANALYSIS
All results were compared using an unpaired t-test (two-tailed)
or One-Way ANOVA. Differences were considered statistically
significant at a P-value <0.05.
RESULTS
MATURATION OF BM-DCs IS INDUCED BY rHsp70 OR rHsp70C′-PSA
Maturation of DCs was determined by the cellular distribution of
LAMP1 andMHCclass IImolecules and the expression of specific
cell surface markers. Figure 1 shows LAMP1 and MHC class II
molecule staining of immature BM-DCs that were left untreated
(control row) or were co-cultured with irradiated-CT26/PSA
cells in the absence (PBS and BSA rows) or presence rHsp70 or
rHsp70C′-PSA. Irradiated-CT26/PSA cells alone did not induce
DC maturation (surface expression of co-stimulatory molecules
and MHC class II, as shown by the MHC class II antigen remain-
ing in the cytoplasm (predominantly in lysosomes) and colocaliz-
ing with LAMP1. In contrast, in lipopolysaccharide (LPS)-treated
immature BM-DCs (positive control; 10μg/ml of LPS for 24 h)
and in BM-DCs cocultured with irradiated CT26/PSA cells and
rHsp70 or rHsp70C′-PSA, high levels of MHC class II antigen
moved to the plasma membrane and LAMP1 was seen as clus-
ters in the cytoplasm (white arrow), indicating maturation of
FIGURE 1 | Irradiated-CT26/PSA cells cause BM-DC maturation in the
presence of rHSPs. BM-DCs (1.5 × 106 in 1ml) were incubated with
medium alone (control) or LPS (10μg/ml) or were cocultured with
irradiated-CT26/PSA cells (1.5 × 106 in 1ml) in PBS or 10μg/ml of BSA,
rHsp70, or rHsp70C′ -PSA. After 48 h, the cells were harvested and stained
with antibodies against MHC class II molecule I-Ad and LAMP1. Column 1,
DAPI nuclear staining; column 2, LAMP1 staining; column 3, MHC class II
intracellular staining; column 4, merged images. Images were acquired
using confocal microscopy at a magnification of ×400. This experiment was
repeated three times with reproducible results. Scale bars, 20μm.
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BM-DCs (Chow et al., 2002; Blander and Medzhitov, 2006). We
also tested for phenotypic changes on DC maturation. Table 1
shows that most of the cells were DCs (positive for CD11c and
MHC class II antigen) and that rHsp70 and rHsp70C′-PSA upreg-
ulated the expression of the mouse DCmaturationmarkers CD86
and DEC205 on BM-DCs incubated with irradiated CT26/PSA
cells to a similar level. Radiation-induced apoptosis of CT-26/PSA
cells was confirmed. As shown in Figure A1A. Addition of exoge-
nous Hsp70 or Hsp70/PSA (fourth and fifth panels) did not
increase the percentage of apoptotic cells after RT compared to
PBS or BSA. There was no significant difference in antigen uptake
rate in the presence of exogenous Hsp70 or Hsp70/PSA compared
to PBS or BSA (Figure A1B). RT alone resulted in expression of
low levels of Hsp70 on the CT26/PSA cells which was not released
into the culture supernatant (Figure A1C).
rHsp70 OR rHsp70C′-PSA ACTIVATES BM-DCs TO RELEASE CYTOKINES
DC activation is characterized by cytokine release. As shown in
Figure 2, incubation with irradiated CT26/PSA cells alone (PBS
or BSA on Figure) did not induce IL-12 and TNF-α secretion by
BM-DCs. However, addition of rHsp70 or rHsp70C′-PSA to the
culture medium-induced a significant increase in IL-12 and TNF-
α release, as did incubation of BM-DCs with LPS. The cytokine-
releasing effects of rHsp70 and rHsp70C′-PSA were not due to
endotoxin contamination, as addition of the endotoxin antagonist
polymyxin B did not affect the cytokine release.
rHsp70 OR rHsp70C′-PSA ENHANCES RT-DC IMMUNOTHERAPY
EQUALLY
BM-DCs alone or together with Hsp70 or Hsp70C′-PSA were
injected into the tumor site 2 days after 8Gy of irradiation. Two
days later, some of the tumor mass was removed for immunohis-
tochemical staining, and the rest mice were measured for tumor
size every 2 or 3 days until death (tumor size > 3000mm3).
The degree of tumor apoptosis before treatment was assessed
by TUNEL and Annexin V staining (Figure A2). As shown in
Figure 3A, RT-DC immunotherapy delayed tumor growth, but
the results did not differ from those for RT alone. However,
injection of rHSPs with RT-DC immunotherapy resulted in sig-
nificant growth delay compared to RT or RT-DC alone (P <
0.05), with no difference between groups of Hsp70C′-PSA and
FIGURE 2 | Exogenous rHSPs enhance the expression of
pro-inflammatory cytokines. BM-DCs (1.5 × 106 in 1ml) were incubated
with medium alone (control) or LPS (10μg/ml) or were cocultured at 37◦C
for 24 h with irradiated-CT26/PSA cells (1.5 × 106 in 1ml) of PBS or
10μg/ml of BSA, rHsp70, or rHsp70C′ -PSA in the absence or presence of
10μg/ml of polymyxin B. The supernatants were then harvested and the
concentration of IL-12 (A) or TNF-α (B) measured by ELISA. The data are
the mean ± SD for three-independent experiments. ∗ Indicates p < 0.05.
Hsp70. Seven days after BM-DC injection, the mice were sacri-
ficed and their spleen cells assessed for their ability to mediate
specific killing of CT26/PSA cells. As shown in Figure 3B, specific
cytotoxicity was higher in mice co-injected with DCs and rHSPs
than with DCs alone or RT alone, with no significant difference
Table 1 | DC surface marker expression after incubation with irradiated CT26/PSA cells in the presence or absence of Hsp70 or Hsp70C′-PSAa.
CT26/PSA (RT)
Marker Control LPS PBS BSA Hsp70 Hsp70C′-PSA
CD11c 94 ± 3 91 ± 2 93 ± 3 95 ± 1 92 ± 4 96 ± 2
CD86 9 ± 5 35 ± 4 10 ± 3 11 ± 4 42 ± 12 67 ± 10
MHC class II 96 ± 3 93 ± 3 95 ± 2 97.2 97.8 97.5
DEC205 4 ± 4 14 ± 5 4 ± 4 4 ± 3 17 ± 10 16 ± 5
aBM-DCs (day 8 cultures) were cultured with medium (negative control) or 10 mg/ml of LPS (positive control) for 24 h or with irradiated CT26/PSA cells in PBS alone
or PBS containing 10 mg/ml of BSA, Hsp70, or HspP70C’-PSA for 24 h; then the cells were harvested and stained with antibodies against MHC class II antigen
(I-Ad), CD11C, CD86, or DC205 and analyzed by flow cytometry. Values are given as the percentage of gated regions after subtraction of the percentage of cells
stained with normal mouse IgG. The data are the mean for three independent experiments.
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FIGURE 3 | Tumor growth inhibition, tumor-specific CTLs and tumor
CD3+ T cell infiltration assay. (A) Mice were injected with 1 × 105
CT26/PSA tumor cells s.c. on day 0 and treated with 8Gy of RT on day 14
followed by immunotherapy in different groups. Each treatment group
included 6 mice. Mean volume ratio, with SD for each group, is plotted vs.
days after tumor-cell inoculation. (B) Seven days after treatment
immunotherapy, splenocytes were harvested for CTLs assay. The cytotoxic
activity of the splenocytes were determined by 51Cr-release assay at various
effector/target cells (E/T) ratios. The data are shown as the mean specific
lysis ± SD for three experiments. ∗Indicates p < 0.05.
between the groups treated with rHsp70 or rHsp70C′-PSA. The
lytic activity of the cultured spleen cells correlated well with
the degree of tumor growth inhibition in each group shown in
Figure 3A. RT-DC immunotherapy elicited a significant increase
in T cell-mediated cytotoxicity compared to control mice, while
RT alone had no significant effect. A greater infiltration of CD3+
T cells were observed when rHsp70 (+ + +) or rHsp70C′-PSA
(+ + +) were co-injected with BM-DCs immunotherapy com-
pared to mice injected with PBS (+) or BM-DCs (+) alone
(Figure A3). There was no difference in the percentage of CD4+
and CD8+ cells in the infiltrated T cells between all groups (data
not show).
rHsp70 OR rHsp70C′-AFP ENHANCES RT-DC IMMUNOTHERAPY
EQUALLY
To prove rHsp70 can serve as all-purpose adjuvant instead of
specific Hsp-fusion peptide, we constructed another recom-
binant tumor antigen (rAFP) and Hsp70 fusion protein
(rHsp70C′-AFP). As shown in Figure 4, co-injection of rHsp70
or rHsp70C′-AFP with RT-DC immunotherapy significantly
enhanced the growth inhibition effect than RT alone, RT-
DC alone or RT-DC plus rAFP. Again, there is no difference
between groups of Hsp70C′-AFP and Hsp70. The addition of
rAFP did not show tumor growth inhibition indicated that
the effect is not the result of a contamination in protein
purification.
rHsp70 OR rHsp70C′-PSA COULD NOT ENHANCE RT WITHOUT DC
In final step, we further investigated whether rHsp70 or
rHsp70C′-PSA enhance RT without DC immunotherapy or
not. There were no significantly differences in tumor growth
FIGURE 4 | Tumor growth inhibition assay in rHsp70/rAFP model. Mice
were injected with 1 × 105 CT26/AFP tumor cells s.c. on day 0 and treated
with 8Gy of RT on day 14 followed by immunotherapy in different groups.
Each treatment group included 6 mice. Mean volume ratio, with SD for each
group, is plotted vs. days after tumor-cell inoculation. ∗Indicates p < 0.05.
inhibition between RT alone, co-injection of rHsp70 or
rHsp70C′-PSA with RT (Figure 5). This result supported our
hypothesis that DC plays the major role in RT enhancement and
rHsp70 was served as adjuvant.
www.frontiersin.org October 2012 | Volume 2 | Article 149 | 5
Wang et al. Recombinant Hsp70 enhances RT and DC
FIGURE 5 | Tumor growth inhibition assay in rHsp70/rPSA without DC.
Mice were injected with 1 × 105 CT26/PSA tumor cells s.c. on day 0 and
treated with 8Gy of RT on day 14 followed by intratumoral injection 50μg
of rHsp70, or rHsp70C′ -PSA. Each treatment group included 6 mice. Tumor
volume (mm3), with SD for each group, is plotted vs. days after tumor-cell
inoculation. ∗Indicates p < 0.05.
DISCUSSION
We have previously reported that intratumoral injection of
immature DCs into the irradiated tumor (RT-DC treatment)
elicits tumor-specific immunity in hepatocellular carcinoma
patients (Chi et al., 2005). The present study suggests that co-
injection of rHsp70 with DCs can enhance the efficacy of RT-DC
immunotherapy, providing the basis for a future clinical protocol.
Irradiation of a tumor may not result in as immunogenic
apoptotic cells as ultraviolet irradiation or hyperthermia (Sierra-
Rivera et al., 1993; Matsumoto et al., 1995; Mukhopadhaya et al.,
2007). In our study, incubation of stressed, but not non-stressed,
apoptotic tumor cells with syngeneic DCs-induced protective
immunity, indicating that uptake of apoptotic cells by DCs alone
may not efficient enough to activate the immune response, as
reported by others (Feng et al., 2002). The presence of Hsp70
on the surface of heat-stressed tumor cells plays a critical role
in enhancing their immunogenicity (Feng et al., 2002). The sec-
ondary signals needed to activate DC function are induced by
danger molecular pattern proteins, such as calreticulin, HSPs,
and high mobility group box 1 (Brusa et al., 2009). HSPs are
generally regarded as protectors of cells against various stresses,
such as ischemia, heat, chemotherapy, or radiation (Ciocca and
Calderwood, 2005). However, HSPs are also associated with the
processing of antigenic peptides and their translocation from the
cytosol to the endoplasmic reticulum (Hartl and Hayer-Hartl,
2002). HSP-peptides or HSP-antigen genes have been success-
fully used as vaccine adjuvants in adaptive immunity (Chen et al.,
2000; Zeng et al., 2006; Zhang et al., 2007). However, there have
not been any reports of the use of exogenous recombinant HSP,
together with radiation, to modulate the local tumor response and
immune response.
The exogenous addition of rHsp70 or rHsp70 fusion pro-
teins did not enhance the phagocytic ability of DCs in vitro, but
resulted in upregulation of co-stimulatory molecules on the DC
surface with DC maturation. Secretion of IL-12 and TNF-α was
induced by adding rHsp70 or rHsp70C′-PSA to the irradiated
tumor cell/DC cultures. These data are consistent with those from
other studies (Gallucci et al., 1999; Lutz et al., 1999; Feng et al.,
2002) showing that apoptotic cells cannot stimulate DC activa-
tion efficiently in the absence of inflammatory signals. Candido
et al. (2001) reported that intratumoral administration of BM-
DCs can partially inhibit the growth of an established tumor,
but co-administration of TNF-α leads to a greater DC-mediated
anti-tumor effect.
The finding that co-injection of DCs and rHsp70C′-PSA or
rHsp70C′-AFP did not result in a greater CTL response than co-
injection of DCs and rHsp70, both in vitro and in vivo, may be
important, as it suggests that recombinant HSP can serve as an
all-purpose adjuvant in RT-DC immunotherapy. It seems that the
anti-tumor immunity provoked by RT-DC is not PSA or AFP-
specific, but CT-26 cell-specific. In a parallel CTL assay using
CT-26 parental cells as targets, addition of rHsp70 or rHsp70C′-
PSA resulted in comparable lysis to that seen using CT-26/PSA
cells as targets (data not shown). Unidentified tumor-specific
antigens more immunogenic than PSA or AFP may also exist. As
antigen shift is always a problem in immunotherapy, the ther-
apeutic effect of specific immunotherapies may only last for a
while. The combination of RT, as both a tumorcidal method and
as a releaser of tumor antigens, with an all-purpose adjuvant, such
as HSPs and DCs, may have been clinically useful. RT can be eas-
ily delivered to tumor sites more precisely thanmost other clinical
modalities. Site-directed injection of immature DCs into apop-
totic tumor cells a few days after RT has proved clinically feasible
and effective. Exogenous addition of recombinant HSPs can fur-
ther activate signals to prime the CTL response.We have reported,
hepatoma may be a suitable target for this protocol. We are now
applying for a clinical trial on high-risk prostate cancer which can
be suitable for hypofractionated RT.
In summary, we have found an efficient method for turn-
ing radiation-induced local apoptosis into a systemic anti-tumor
immune response. Co-injection of rHsp70 and DCs into the irra-
diated tumor site induced a more potent anti-tumor immune
response than injection of DCs alone. rHsp70 was as effective
as rHsp70C′-PSA or rHsp70C′-AFP in inducing a tumor-specific
CTL response or tumor growth delay. The combined use of RT-
DC and recombinant HSP as an all purpose adjuvantmay convert
non- or low-immunogenic tumor cells to higher immunogenicity
through promotion of DC function.
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APPENDIX
APOPTOSIS OF IRRADIATED CT-26/PSA CELLS AND PHAGOCYTOSIS
CT-26/PSA cells were stained with PKH 67 (Sigma, St Louis, MO,
USA) according to the manufacturer’s protocol, then the labeled
tumor cells were irradiated to induce apoptosis. Apoptosis was
confirmed at 24 h after RT using an Annexin V Apoptosis Kit (BD
Pharmingen). Day 9 BM-DCs stained with PKH-67 (5 × 105 in
1ml) were cocultured with γ irradiated CT-26/PSA cells stained
with Cell Tracker (Molecular Probes, Eugene, OR, USA) (5 × 105
in 1ml) for 24 h at either 4◦C (no phagocytosis control) or
37◦C (experimental group), then phagocytosis by BM-DCs was
analyzed by flow cytometry.
FIGURE A1 | Exogenous rHsp70 did not increase radiation–induced
CT26/PSA apoptosis nor increase BM-DC phagocytosis. (A) The
percentage of apoptotic CT26/PSA cells was analyzed by annexin-V and
PI (propidium iodide) staining (shown in the upper right corner) in, left to
right, parental CT26/PSA cells in PBS (parental CT26) or irradiated
CT26/PSA cells (irradiated CT26) in PBS (PBS) or 10μg/ml of BSA (BSA),
rHsp70 (HSP70), or rHsp70C′ -PSA (Hsp70/PSA) for 24 h incubation. The
number of percentage was indicated AnnexinV-positive cells. (B) Cell
Tracker-labeled CT26/PSA (5 × 105), pretreated as in Figure 1A, and
PKH-67-labeled BM-DCs (5 × 105) were cocultured in 6-well plates for
24 h at 4◦C (top row, no phagocytosis control) or 37◦C (bottom row) and
the percentages of double-positive cells measured. The panels are
arranged in the same order as in Figure 1A. (C) Untreated (lane C) or
irradiated CT26/PSA cells (lane RT) or control cells heated at 42◦C for
30min (positive control; lane 42) were harvested for Western blot
analysis for Hsp70 protein in the cell lysate and culture supernatant. Lane
rHsp is rHsp70. These data are representative of those obtained in three
experiments.
WESTERN BLOT ANALYSIS
For protein analysis, cells were lysed for 5min at room tem-
perature in a buffer composed of 150mmol/L NaCl, 50mmol/L
Tris (pH 8.0), 5mmol/L EDTA, 1% (v/v) Nonidet P-40,
1mmol/L of phenylmethylsulfonyl fluoride, 20μg/ml of apro-
tinin, and 25μg/ml of leupeptin and the protein concen-
tration of the lysates measured using Bio-Rad protein assay
reagent. Cell lysates (100μg) were electrophoresed on a 12%
SDS polyacrylamide gel and the proteins transferred to an
Immobilon-P PVDFmembrane (Millipore, Bedford, MA), which
was then blocked for 2 h at room temperature in PBS-0.05%
Tween 20 containing 10% nonfat milk, then incubated with
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anti-Hsp70 antibodies (SPA810; Stressgen, San Diago, CA)
for 2 h at room temperature in PBS-0.05% Tween 20 con-
taining 5% nonfat milk, then for 1 h at room temperature
with horseradish peroxidase-conjugated secondary antibod-
ies (Jackson ImmunoResearch Laboratories, West Grove,
PA) in the same buffer. Blots were developed using a
chemiluminescent detection system (ECL; GE Life Science,
Buckinghamshire, UK).
Apoptosis assessment
Apoptosis in the tumor tissue was assessed using the ter-
minal deoxynucleotidyl transferase-mediated dUTP-biotin
nick end-labeling (TUNEL) assay performed using a commercial
TdT-FragEL™ DNA fragmentation detection kit (Oncogene
Research, Darmstadt, Germany). Briefly, tumor tissue was excised
from the mouse and embedded in paraffin sections. After
hydration and dehydration, the slides were fixed with 4%
paraformaldehyde in PBS overnight and permeabilized with
20mg/ml of proteinase K in 10mM Tris pH 8 for 10min
at room temperature. Endogenous peroxidases were inacti-
vated by incubation with 3% H2O2 in methanol for 5min at
room temperature, then, after washing, the cells were incu-
bated with biotin-labeled dNTPs in the presence of termi-
nal deoxynucleotidyl transferase enzyme solution for 1.5 h at
37◦C and biotinylated nucleotides detected by incubation with
a streptavidin-horseradish peroxidase conjugate for 25min at
room temperature, followed by incubation with diaminoben-
zidine for 15min at room temperature. Finally, tumor cells
were counterstained with methyl green for 3min at room
temperature.
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FIGURE A2 | In vivo tumor apoptosis assay. CT26/PSA cells (1 × 105)
were injected s.c. on day 0. On day 14, the tumor size was around 4mm in
diameter and the mice were left untreated (A) or received 8Gy of RT (B),
then, on day 16, sections from the tumor site were analyzed using the
TUNEL assay. Apoptotic cells are stained brown (magnification, 100 ×).
(C) The tumor mass was digested with collagenase and analyzed by
annexin V staining; the apoptotic cells are expressed as the percentage of
annexin V-positive cells. The data represent the mean ± SD for three mice.
∗Indicates p < 0.05.
FIGURE A3 | (A–D) Four days after RT-DC immunotherapy, the tumor
were removed and analyzed by immunohistochemistry. CD3+ T cell
infiltration is seen as brown spots in the section counterstained with
hematoxylin (magnification, 400 ×). Sections are from mice treated
with PBS (A), BM-DCs alone (B) or BM-DCs plus 50μg of rHsp70 (C)
or rHsp70C′ -PSA (D).
